Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut bacteria linked to chemo success in aggressive breast cancer

NCT ID NCT03586297

First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 40 times

Summary

This study looked at whether the types of bacteria in the gut and inside tumors affect how well chemotherapy works in triple negative breast cancer. Researchers followed 49 patients receiving standard chemotherapy before surgery. They collected samples to see if certain bacteria were linked to a complete response, where no cancer remains after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Georgetown University

    Washington D.C., District of Columbia, 20057, United States

  • Hackensack Meridian Health

    Hackensack, New Jersey, 07601, United States

  • Yale University - Yale Cancer Center

    New Haven, Connecticut, 06520-8327, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors predict which patients will respond best to chemotherapy based on their gut bacteria.

What could go wrong

This is a small, completed observational study. It does not test a new treatment, so results may not lead to immediate changes in care.

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.